Salmeterol free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522405

CAS#: 89365-50-4 (free base)

Description: Salmeterol is a long-acting beta2-adrenergic receptor agonist drug used in the maintenance and prevention of asthma symptoms and maintenance of chronic obstructive pulmonary disease (COPD) symptoms. Salmeterol is also used to prevent breathing difficulties during exercise (exercise induced bronchospasm). It is marketed as Serevent in the US.

Chemical Structure

img
Salmeterol free base
CAS# 89365-50-4 (free base)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 522405
Name: Salmeterol free base
CAS#: 89365-50-4 (free base)
Chemical Formula: C25H37NO4
Exact Mass: 415.27
Molecular Weight: 415.570
Elemental Analysis: C, 72.26; H, 8.97; N, 3.37; O, 15.40

Price and Availability

Size Price Availability Quantity
5mg USD 375 2 weeks
10mg USD 550 2 weeks
50mg USD 1000 2 Weeks
100mg USD 1450 2 Weeks
Bulk inquiry

Related CAS #: 89365-50-4 (free base)   94749-08-3 (xinafoate)    

Synonym: Salmeterol free base; Astmerole; GR 33343 X; GR 33343X; GR33343X; GR-33343X; SN408D.

IUPAC/Chemical Name: 4-Hydroxy-alpha1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol

InChi Key: GIIZNNXWQWCKIB-UHFFFAOYSA-N

InChi Code: InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2

SMILES Code: OC(CNCCCCCCOCCCCC1=CC=CC=C1)C2=CC=C(O)C(CO)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#94749-08-3 (Salmeterol xinafoate salt) CAS#89365-50-4 (Salmeterol free base).

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively.
In vitro activity: This study investigated the anti-inflammatory effects of salmeterol on LPS-activated murine microglial BV2 cells. Salmeterol inhibited LPS-induced release of TNF-α, IL-1β, and NO in BV2 cells. Salmeterol suppressed nuclear translocation of NF-κB p65 by inhibiting the IκB-α degradation and TAK1 phosphorylation. Salmeterol increased the expression of β-arrestin2 and enhanced the interaction between β-arrestin2 and TAB1. Reference: J Neuroimmunol. 2018 Dec 15;325:10-19. https://pubmed.ncbi.nlm.nih.gov/30352316/
In vivo activity: Salmeterol shows promise in combating stress-related disruptions in adult hippocampal neurogenesis and depressive behavior. It enhances neuroplasticity in the hippocampus, fostering the development of neuroblasts with increased complexity. These benefits are primarily observed in the ventral hippocampus, which plays a role in emotional behavior and mood regulation. Reference: Front Pharmacol. 2019 Sep 12;10:1000. https://pubmed.ncbi.nlm.nih.gov/31572182/

Preparing Stock Solutions

The following data is based on the product molecular weight 415.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Sharma M, Flood PM. β-arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells. J Neuroimmunol. 2018 Dec 15;325:10-19. doi: 10.1016/j.jneuroim.2018.10.001. Epub 2018 Oct 4. PMID: 30352316. 2. Haghi M, Traini D, Postma DS, Bebawy M, Young PM. Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology. 2013 Nov;18(8):1197-201. doi: 10.1111/resp.12146. PMID: 23796052. 3. Bortolotto V, Bondi H, Cuccurazzu B, Rinaldi M, Canonico PL, Grilli M. Salmeterol, a β2 Adrenergic Agonist, Promotes Adult Hippocampal Neurogenesis in a Region-Specific Manner. Front Pharmacol. 2019 Sep 12;10:1000. doi: 10.3389/fphar.2019.01000. PMID: 31572182; PMCID: PMC6751403. 4. Han SO, Li S, Koeberl DD. Salmeterol enhances the cardiac response to gene therapy in Pompe disease. Mol Genet Metab. 2016 May;118(1):35-40. doi: 10.1016/j.ymgme.2016.03.006. Epub 2016 Mar 18. PMID: 27017193; PMCID: PMC4833676.
In vitro protocol: 1. Sharma M, Flood PM. β-arrestin2 regulates the anti-inflammatory effects of Salmeterol in lipopolysaccharide-stimulated BV2 cells. J Neuroimmunol. 2018 Dec 15;325:10-19. doi: 10.1016/j.jneuroim.2018.10.001. Epub 2018 Oct 4. PMID: 30352316. 2. Haghi M, Traini D, Postma DS, Bebawy M, Young PM. Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology. 2013 Nov;18(8):1197-201. doi: 10.1111/resp.12146. PMID: 23796052.
In vivo protocol: 1. Bortolotto V, Bondi H, Cuccurazzu B, Rinaldi M, Canonico PL, Grilli M. Salmeterol, a β2 Adrenergic Agonist, Promotes Adult Hippocampal Neurogenesis in a Region-Specific Manner. Front Pharmacol. 2019 Sep 12;10:1000. doi: 10.3389/fphar.2019.01000. PMID: 31572182; PMCID: PMC6751403. 2. Han SO, Li S, Koeberl DD. Salmeterol enhances the cardiac response to gene therapy in Pompe disease. Mol Genet Metab. 2016 May;118(1):35-40. doi: 10.1016/j.ymgme.2016.03.006. Epub 2016 Mar 18. PMID: 27017193; PMCID: PMC4833676.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Liu S, Watts AB, Du J, Bui A, Hengsawas S, Williams RO 3rd. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery. Eur J Pharm Biopharm. 2015 Jul 26. pii: S0939-6411(15)00317-3. doi: 10.1016/j.ejpb.2015.07.017. [Epub ahead of print] PubMed PMID: 26220015.

2: Anwar MM, El-Haggar RS, Zaghary WA. Salmeterol Xinafoate. Profiles Drug Subst Excip Relat Methodol. 2015;40:321-69. doi: 10.1016/bs.podrm.2015.02.002. Epub 2015 Apr 1. Review. PubMed PMID: 26051688.

3: Hassoun M, Ho S, Muddle J, Buttini F, Parry M, Hammond M, Forbes B. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers. Int J Pharm. 2015 Jul 25;490(1-2):360-7. doi: 10.1016/j.ijpharm.2015.05.028. Epub 2015 May 15. PubMed PMID: 25987210.

4: Bi S, Wang T, Wang Y, Zhao T, Zhou H. Using gold nanoparticles as probe for detection of salmeterol xinafoate by resonance Rayleigh light scattering. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Jan 25;135:1074-9. doi: 10.1016/j.saa.2014.08.010. Epub 2014 Aug 19. PubMed PMID: 25173524.

5: Zhao T, Bi S, Wang Y, Wang T, Pang B, Gu T. In vitro studies on the behavior of salmeterol xinafoate and its interaction with calf thymus DNA by multi-spectroscopic techniques. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Nov 11;132:198-204. doi: 10.1016/j.saa.2014.04.158. Epub 2014 May 9. PubMed PMID: 24866086.

6: Restrepo RD, Tate A, Coquat J. Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Oct;14(14):1993-2002. doi: 10.1517/14656566.2013.823949. Epub 2013 Jul 31. Review. PubMed PMID: 23898819.

7: Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD. Manag Care. 2011 Aug;20(8):46-50, 53-5. PubMed PMID: 21887993.

8: Harrison LI, Novak CC, Needham MJ, Ratner P. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. J Aerosol Med Pulm Drug Deliv. 2011 Oct;24(5):245-52. doi: 10.1089/jamp.2011.0884. Epub 2011 Jun 14. PubMed PMID: 21671752.

9: Kasaye L, Hymete A, Mohamed AM. HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in dry powder inhalers. Saudi Pharm J. 2010 Jul;18(3):153-9. doi: 10.1016/j.jsps.2010.05.001. Epub 2010 May 31. PubMed PMID: 23964174; PubMed Central PMCID: PMC3731032.

10: Mostafapour E, Mousavi SA, Shahmiri SS, Fereshtehnejad SM. Effects of combination of fluticasone propionate and salmeterol xinafoate on lung function improvement in patients with bronchiectasis. Lijec Vjesn. 2009 Nov;131 Suppl 6:8-11. PubMed PMID: 22046624.